0001213900-24-006637.txt : 20240126 0001213900-24-006637.hdr.sgml : 20240126 20240125200416 ACCESSION NUMBER: 0001213900-24-006637 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231116 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240126 DATE AS OF CHANGE: 20240125 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABVC BIOPHARMA, INC. CENTRAL INDEX KEY: 0001173313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 260014658 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40700 FILM NUMBER: 24563804 BUSINESS ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 510-668-0881 MAIL ADDRESS: STREET 1: 44370 OLD WARM SPRINGS BLVD. CITY: FREMONT STATE: CA ZIP: 94538 FORMER COMPANY: FORMER CONFORMED NAME: American BriVision (Holding) Corp DATE OF NAME CHANGE: 20160111 FORMER COMPANY: FORMER CONFORMED NAME: METU BRANDS, INC. DATE OF NAME CHANGE: 20150908 FORMER COMPANY: FORMER CONFORMED NAME: ECOLOGY COATINGS, INC. DATE OF NAME CHANGE: 20080821 8-K/A 1 ea192147-8ka1_abvcbio.htm AMENDMENT NO. 1 TO FORM 8-K
true 0001173313 0001173313 2023-11-16 2023-11-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K/A

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 25, 2024 (November 16, 2023)

 

ABVC BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40700   26-0014658
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

44370 Old Warm Springs Blvd.

Fremont, CA

   94538
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number including area code: (510) 668-0881

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of each exchange on which registered
Common Stock, par value $0.001 per share   ABVC   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

 

Explanatory Note

 

This Current Report on Form 8-K/A (this “Amendment”) is being filed by the Company to amend the Current Report on Form 8-K (the “Prior 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2023, in connection with the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entering into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”), pursuant to which the Company acquired a controlling interest over AIBL (the “Acquisition”).

 

The Company is filing this Amendment solely to provide (i) the historical audited financial statements of AIBL for the period from January 10, 2023 (inception) until September 30, 2023, referred to in Item 9.01(a) below and (ii) the unaudited pro forma condensed combined financial statements as of and for the nine-month period ended September 30, 2023, referred to in Item 9.01(b) below.

 

1

 

 

Item 9.01 Financial Statement and Exhibits

 

(a) Financial Statements of Business Acquired

 

The audited financial statements of AIBL for the period from January 10, 2023 until September 30, 2023 are attached hereto as Exhibit 99.1.

 

(b) Pro Forma Financial Information.

 

The unaudited pro forma condensed combined balance sheet of the Company and AIBL as of September 30, 2023, the unaudited pro forma condensed combined statements of operations for the nine months ended September 30, 2023, and the notes related thereto, reflecting the transaction (“Transaction”), are attached hereto as Exhibit 99.2 and incorporated herein by reference.

 

(d) Exhibits

 

Exhibit No.   Description
23.1   Consent of WWC, P.C.
99.1   Audited financial statements of AIBL for the period from January 10, 2023 until September 30, 2023.
99.2   Unaudited pro forma condensed combined statement of operations of the Company and AIBL as of and for the nine months ended September 30, 2023.
104   Cover Page Interactive Data File, formatted in Inline XBRL

 

2

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABVC BioPharma, Inc.
   
January 25, 2024 By: /s/ Uttam Patil
    Uttam Patil
    Chief Executive Officer

 

 

3

 

 

 EX-23.1 2 ea192147ex23-1_abvcbio.htm CONSENT OF WWC, P.C

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in Registration Statement on Form S-3 (File No. 333-260588), Registration Statement on Form S-8 (File No. 333-234656) of ABVC BioPharma, Inc. of our report dated January 25, 2024, relating to the financial statements of AIBTL BIOPHARMA INC., appearing in this Current Report on Form 8-K/A dated January 25, 2024.

 

/s/ WWC, P.C.  
WWC, P.C.  
   
January 25, 2024  

 

 EX-99.1 3 ea192147ex99-1_abvcbio.htm AUDITED FINANCIAL STATEMENTS OF AIBL FOR THE PERIOD FROM JANUARY 10, 2023 UNTIL SEPTEMBER 30, 2023

Exhibit 99.1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To: The Board of Directors and Stockholders of
  AiBtl BioPharma Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying balance sheets of AiBtl BioPharma Inc. (the “Company”) as of September 30, 2023, and the related statements of operations and comprehensive loss, cash flows and stockholders’ deficit for the period from January 10, 2023 (inception) to September 30, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023, and the results of its operations and its cash flows for the period from January 10, 2023 (inception) to September 30, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 2, the Company needs to raise additional funds to meet its obligations and sustain its operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

/s/ WWC, P.C.  
WWC, P.C.  
Certified Public Accountants  
PCAOB ID No. 1171  

 

We have served as the Company’s auditor since 2024
San Mateo, California

 

January 25, 2024

 

 

 

 

AIBTL BIOPHARMA INC.

BALANCE SHEETS

 

   September 30,
2023		 
ASSETS    
Current Assets    
Cash and cash equivalents  $- 
Total Current Assets   - 
      
Total Assets  $- 
      
LIABILITIES AND EQUITY     
Current Liabilities     
Accrued expense   597,388 
Total Current Liabilities   597,388 
      
Due to director   498 
Total Liabilities   597,886 
      
COMMITMENTS AND CONTINGENCIES     
      
Stockholders’ Deficit     
Common stock, $0.0001 par value, 100,000,000 authorized, 0 shares issued and outstanding as of September 30, 2023     
Accumulated deficit   (597,886)
Total Stockholder’s Deficit   (597,886)
      
Total Liabilities and Stockholder’s Deficit  $- 

 

2

 

 

AIBTL BIOPHARMA INC.

STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

 

   From
January 10,
2023 (Inception) to
September 30,
2023		 
Revenues  $- 
      
Cost of revenues   - 
      
Gross (loss) profit   - 
      
Operating expenses     
Selling, general and administrative expenses   597,886 
Total operating expenses   597,886 
      
Loss from operations   (597,886)
      
Other income (expense)     
Total other (expense) income   - 
      
Loss before income tax   (597,886)
      
Provision for (benefit from) income tax   - 
      
Net loss   (597,886)

 

3

 

 

AIBTL BIOPHARMA INC.

STATEMENTS OF CASH FLOWS

 

   From
January 10,
2023 (Inception) to
September 30,
2023		 
Cash flows from operating activities    
Net loss  $(597,886)
Adjustments to reconcile net loss to net cash used in operating activities:     
Changes in operating assets and liabilities:     
Increase in accrued expenses   597,338 
Increase in due to director   498 
Net cash used in operating activities   - 
      
Cash flows from investing activities     
Net cash used in investing activities   - 
      
Cash flows from financing activities     
Net cash provided by financing activities   - 
      
Effect of exchange rate changes on cash and cash equivalents and restricted cash   - 
      
Net decrease in cash and cash equivalents and restricted cash   - 
      
Cash and cash equivalents and restricted cash     
Beginning   - 
Ending  $- 
      
Supplemental disclosure of cash flows     
Cash paid during the year for:     
Interest expense paid   - 
Income tax paid  $- 

 

4

 

 

AIBTL BIOPHARMA INC.

STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE PERIOD FROM JANUARY 10, 2023 (INCEPTION) TO SEPTEMBER 30, 2023

 

   Common Stock   Additional       Accumulated
Other		    
   Number of
shares		   Amounts   Paid-in
Capital		   Accumulated
Deficit		   Comprehensive
Income		   Total
Deficit		 
Balance at January 10, 2023 (Inception)          -   $        -   $     -   $       -   $         -   $ - 
Net loss for the period   -    -    -    (597,886)   -    (597,886)
Balance at September 30, 2023   -   $-   $-   $(597,886)  $-   $(597,886)

 

5

 

 

1. ORGANIZATION AND DESCRIPTION OF BUSINESS

 

AiBtl BioPharma Inc. (“AIBL”), a Delaware company, was incorporated on January 10, 2023. AIBL is a development stage biotech company focused on therapeutics targeting the human central nervous system by developing life-changing medicine and medical devices for patients with serious unmet needs. AIBL's office is located in 44370 Old Warm Springs Blvd., CA 94538

 

2. LIQUIDITY AND GOING CONCERN

 

The accompanying financial statements have been prepared in conformity with U.S. GAAP which contemplates continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are settled in the ordinary course of business at amounts disclosed in the financial statements. The Company’s ability to continue as a going concern depends upon its ability to raise additional funds to meet its obligations and sustain its operations. For the period from inception (January 10, 2023) to September 30, 2023, the Company reported net loss of $498. As of September 30, 2023, the Company does not have cash and cash equivalent for operation. In addition, the Company does not have operations to generate positive cash. These conditions give rise to substantial doubt as to whether the Company will be able to continue as a going concern.

 

To sustain its ability to support the Company’s operating activities, the Company may have to consider supplementing its available sources of funds through the following sources:

 

●cash generated from operations;

 

●fund raising through private equity or other equity method;

 

●other available sources of financing from banks and other financial institutions; and

 

●financial support from the Company’s related party and stockholders.

 

Management has commenced a strategy to raise debt and equity. However, there can be no certainty that these additional financings will be available on acceptable terms or at all. If management is unable to execute this plan, there would likely be a material adverse effect on the Company’s business. All these factors raise substantial doubt about the ability of the Company to continue as a going concern.

 

The financial statements for the period from January 10, 2023 (inception) to September 30, 2023 have been prepared on a going concern basis and do not include any adjustments to reflect the possible future effects on the recoverability and classifications of assets or the amounts and classifications of liabilities that may result from the inability of the Company to continue as a going concern.

 

6

 

 

3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying audited financial statements have been prepared in accordance with the generally accepted accounting principles in the United States of America (the “U.S. GAAP”). All significant intercompany transactions and account balances have been eliminated.

 

The Company’s audited financial statements are expressed in U.S. dollars.

 

Use of Estimates

 

The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the amount of revenues and expenses during the reporting periods. Actual results could differ materially from those results.

 

Cash and Cash Equivalents 

 

The Company considers highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. As of September 30, 2023, the Company’s cash and cash equivalents amounted $0.

 

Concentration of Credit Risk

 

The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments in high quality credit institutions, but these investments may be in excess of the U.S. Federal Deposit Insurance Corporation’s insurance limits. The Company does not enter into financial instruments for hedging, trading or speculative purposes.

 

Selling, general and administrative expenses

 

The Company accounts for the selling, general and administrative expenses. It consists of costs relating to incorporation, and accrued fees to auditors and attorneys, as well as rental expenses.

 

Research and development expense

 

AIBL is expecting to perform research and development activities in the future, due to the licensing agreements signed with ABVC and BioLite. Research and development expenses shall comprise of costs incurred in performing research and development activities, including personnel-related costs, facilities-related overhead, and outside contracted services including clinical trial costs, manufacturing and process development costs for both clinical and preclinical materials, research costs, and other consulting services.

 

4. SUBSEQUENT EVENTS

 

In November 2023, AIBL has entered two multi-year, global licensing agreements with both ABVC BioPharma, Inc. (“ABVC”) and BioLite, Inc. (“BioLite”), for their CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the “Licensed Products”). The potential license will cover the Licensed Products’ clinical trial, registration, manufacturing, supply, and distribution rights. The Licensed Products for MDD and ADHD, owned by ABVC and BioLite, were valued at $667M by a third-party evaluation. The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the respective agreements, each of ABVC and BioLite received 23million shares of AIBL stock at $10 per share, and if certain milestones are met, may receive $3,500,000 and royalties equaling 5% of net sales, up to $100 million.

 

 

7

 

 EX-99.2 4 ea192147ex99-2_abvcbio.htm UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS OF THE COMPANY AND AIBL AS OF AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2023

Exhibit 99.2

 

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

 

On November 12, 2023, the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entered into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”, or the acquired company) for the Company and BioLite’s CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (collectively, the “Licensed Products”). The potential license will cover the Licensed Products’ clinical trial, registration, manufacturing, supply, and distribution rights. The Licensed Products for MDD and ADHD, owned by ABVC and BioLite, were valued at $667M by a third-party evaluation. The parties are determined to collaborate on the global development of the Licensed Products. The parties are also working to strengthen new drug development and business collaboration, including technology, interoperability, and standards development. As per each of the respective agreements, each of ABVC and BioLite received 23 million shares  of AIBL stock (with an expected value of $10 per share) and as a result, the Company has a controlling interest over AIBL. If certain milestones are met, the Company and BioLite are each eligible to receive $3,500,000 and royalties equaling 5% of net sales, up to $100 million.

 

The following unaudited pro forma combined financial information of the Company and AIBL is presented to illustrate the estimated effects of the condensed combined financial statements as of and for the nine-month period ended September 30, 2023.

 

 

 

 

UNAUDITED PRO FORMA COMBINED BALANCE SHEETS

 

   As of September 30, 2023         
   ABVC
BioPharma,
Inc.		   AiBtl
BioPharma
Inc.		   Pro Forma
Adjustments		   Pro Forma
Combined		 
ASSETS                
Current Assets                
Cash and cash equivalents  $500,069   $-           -   $500,069 
Restricted cash   620,868    -    -    620,868 
Accounts receivable, net   1,530    -    -    1,530 
Accounts receivable – related parties, net   624,373    -    -    624,373 
Due from related party – current   535,046    -    -    535,046 
Short-term Investment   68,521    -    -    68,521 
Prepaid expenses and other current assets   143,127    -    -    143,127 
Total Current Assets   2,493,534    -    -    2,493,534 
                     
Property and equipment, net   7,953,936    -    -    7,953,936 
Operating lease right-of-use assets   899,817    -    -    899,817 
Long-term investments   2,677,395    -    -    2,677,395 
Deferred tax assets   34,256    -    -    34,256 
Prepaid expenses – non-current   128,898    -    -    128,898 
Security deposits   44,259    -    -    44,259 
Prepayment for long-term investments   1,429,016    -    -    1,429,016 
Due from related parties – non-current   930,396    -    -    930,396 
Total Assets  $16,591,507   $-    -   $16,591,507 
                     
LIABILITIES AND EQUITY                    
Current Liabilities                    
Short-term bank loans  $852,500   $-    -   $852,500 
Accrued expenses and other current liabilities   3,558,213    597,388    -    4,155,601 
Contract liabilities   79,501    -    -    79,501 
Operating lease liabilities – current portion   392,666    -    -    392,666 
Due to related parties   480,196    -    -    480,196 
Total Current Liabilities   5,363,076    597,388    -    5,960,464 
                     
Tenant security deposit   5,680    -    -    5,680 
Operating lease liability – non-current portion   507,151    -    -    507,151 
Convertible notes payable – third parties   1,654,004    -    -    1,654,004 
Due to Director   -    498    -    498 
Total Liabilities   7,529,911    498    -    8,127,797 
                     
COMMITMENTS AND CONTINGENCIES                    
                     
Equity                    
Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding   -    -    -    - 
Common stock, $0.001 par value, 10,000,000 authorized, 4,823,043 and 3,286,190 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively(1)   4,823    -    -    4,823 
Additional paid-in capital   80,662,290    -    -    80,662,290 
Stock subscription receivable   (677,220)   -    -    (677,220)
Accumulated deficit   (62,309,161)   (597,886)   -    (62,907,047)
Accumulated other comprehensive income   519,123    -    -    519,123 
Treasury stock   (9,100,000)   -    -    (9,100,000)
Total Stockholders’ Equity   9,099,855    (597,886)   -    8,501,969 
Noncontrolling interest   (38,259)   -    -    (38,259)
Total Equity   9,061,596    (597,886)   -    8,463,710 
                     
Total Liabilities and Equity  $16,591,507   $-    -   $16,591,507 

  

(1) Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

2

 

 

UNAUDITED PRO FORMA

COMBINED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS

 

   Nine Months Ended
September 30, 2023		         
   ABVC
BioPharma,
Inc.		   AiBtl
BioPharma
Inc.		   Pro Forma
Adjustments		   Pro Forma
Combined		 
Revenues  $150,265   $-          -   $150,265 
                     
Cost of revenues   162,831    -    -    162,831 
                     
Gross (loss) profit   (12,566)   -    -    (12,566)
                     
Operating expenses                    
Selling, general and administrative expenses   3,841,633    597,886    -    4,439,519 
Research and development expenses   990,731    -    -    990,731 
Stock-based compensation   1,409,969    -    -    1,409,969 
Total operating expenses   6,242,333    597,886    -    6,840,219 
                     
Loss from operations   (6,254,899)   (597,886)   -    (6,852,785)
                     
Other income (expense)                    
Interest income   147,998    -    -    147,998 
Interest expense   (1,390,039)   -    -    (1,390,039)
Operating sublease income   53,900    -    -    53,900 
Gain/Loss on foreign exchange changes   (55,625)   -    -    (55,625)
Other (expense) income   (1,174)   -    -    (1,174)
Total other (expense) income   (1,244,940)   -    -    (1,244,940)
                     
Loss before income tax   (7,499,839)   (597,886)   -    (8,097,725)
                     
Provision for (benefit from) income tax   80,696    -    -    80,696 
                     
Net loss   (7,580,535)   (597,886)   -    (8,178,421)
                     
Net loss attributable to noncontrolling interests   (175,813)   -    -    (175,813)
                     
Net loss attributed to ABVC and subsidiaries   (7,404,722)   -    -    (8,002,608)
Foreign currency translation adjustment   1,995    -    -    1,995 
Comprehensive loss  $(7,402,727)  $(597,886)   -   $(8,000,613)
                     
Net loss per share:                    
Basic and diluted  $(2.08)  $-    -   $(2.25)
                     
Weighted average shares used in computing net loss per share of common stock(1):                    
Basic and diluted   3,555,474    -    -    3,555,474 

 

(1) Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3

 

 

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The pro forma financial information was prepared in conformity with Article 11 of Regulation S-X. The pro forma financial information for acquisitions was prepared using the acquisition method of accounting in accordance with Accounting Standards Codification 805, “Business Combinations” (“ASC 805”) and was derived from the audited historical financial statements of the Company and the acquired company.

 

The pro forma financial information has been prepared by the Company for illustrative and informational purposes only in accordance with Article 11. The pro forma financial information is not necessarily indicative of what the Company’s statement of comprehensive loss or balance sheet actually would have been had the Transaction and other adjustments relating to the Transaction been completed as of the dates indicated or will be for any future periods. The pro forma financial information does not purport to project the Company’s future financial position or results of operations following the completion of the Acquisition.

 

The Company is still in the process of performing a full review of the acquired companies’ accounting policies to determine if there are any additional material differences that require modification or reclassification of the acquired companies’ revenues, expenses, assets or liabilities to conform to the Company’s accounting policies and classifications. As a result of that review, the Company may identify differences between the accounting policies of the companies that, when conformed, could have a material impact on the pro forma financial information.

 

 

4

 

 

 

 GRAPHIC 5 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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abvc-20231116.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 abvc-20231116_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 abvc-20231116_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Nov. 16, 2023
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag true
Amendment Description This Current Report on Form 8-K/A (this “Amendment”) is being filed by the Company to amend the Current Report on Form 8-K (the “Prior 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2023, in connection with the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entering into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”), pursuant to which the Company acquired a controlling interest over AIBL (the “Acquisition”).
Document Period End Date Nov. 16, 2023
Entity File Number 001-40700
Entity Registrant Name ABVC BIOPHARMA, INC.
Entity Central Index Key 0001173313
Entity Tax Identification Number 26-0014658
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 44370 Old Warm Springs Blvd.
Entity Address, City or Town Fremont
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94538
City Area Code 510
Local Phone Number 668-0881
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ABVC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 10 ea192147-8ka1_abvcbio_htm.xml IDEA: XBRL DOCUMENT 0001173313 2023-11-16 2023-11-16 iso4217:USD shares iso4217:USD shares true 0001173313 8-K/A 2023-11-16 ABVC BIOPHARMA, INC. NV 001-40700 26-0014658 44370 Old Warm Springs Blvd. Fremont CA 94538 510 668-0881 false false false false Common Stock, par value $0.001 per share ABVC NASDAQ false This Current Report on Form 8-K/A (this “Amendment”) is being filed by the Company to amend the Current Report on Form 8-K (the “Prior 8-K”) filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2023, in connection with the Company and one of its subsidiaries, BioLite, Inc. (“BioLite”) each entering into a multi-year, global licensing agreement with AiBtl BioPharma Inc. (“AIBL”), pursuant to which the Company acquired a controlling interest over AIBL (the “Acquisition”). EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://abvcpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports abvc-20231116.xsd abvc-20231116_lab.xml abvc-20231116_pre.xml ea192147-8ka1_abvcbio.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea192147-8ka1_abvcbio.htm": { "nsprefix": "ABVC", "nsuri": "http://abvcpharma.com/20231116", "dts": { "schema": { "local": [ "abvc-20231116.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "abvc-20231116_lab.xml" ] }, "presentationLink": { "local": [ "abvc-20231116_pre.xml" ] }, "inline": { "local": [ "ea192147-8ka1_abvcbio.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://abvcpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea192147-8ka1_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea192147-8ka1_abvcbio.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://abvcpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001213900-24-006637-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-006637-xbrl.zip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end